Navigation Links
Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
Date:2/23/2010

the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements describing the Company's anticipated use of proceeds from any sale of securities under the equity facility and its clinical and regulatory goals and partnering strategy with respect to picoplatin. Actual results and events may differ materially from those indicated in these forward-looking statemen
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
2. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
8. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
9. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
(Date:7/30/2015)... 2015  Cleveland Clinic President Wael Barsoum , ... month that industry is compelled to adopt declining reimbursements ... efficiencies—and develop the transformational innovations -- required to thrive ... preceded by Doug Kohrs , past President and ... stressed that industry must add "episode of care," also ...
(Date:7/30/2015)... , July 30, 2015 Future ... report titled, "Continuous Glucose Monitoring Systems Market: Global Industry ... the report, the global continuous glucose monitoring systems market ... is expected to reach US$ 788.4 Mn by 2020, ... 2015 to 2020. Global continuous glucose monitoring ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... presented at 2008 ICAAC/IDSA Joint Meeting, ... a,clinical-stage biopharmaceutical company focused on commercializing,products to ... the,successful demonstration of synergistic activities and improvement ... vitro combination,studies of Sequella lead TB drug ...
... PharmAthene, Inc.,(NYSE ALTERNEXT US: PIP), a biodefense ... today announced,that dosing of volunteers has begun in ... safety and tolerability in humans. Protexia(R),which is produced ... recombinant version,of human butyrylcholinesterase (BChE), which has been ...
Cached Medicine Technology:Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 3PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 4PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 5
(Date:7/31/2015)... ... July 31, 2015 , ... ... to know in predictive health analytics , Jvion continues to disrupt the ... creates predictive software that targets patient and population level illness to drive prevention ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... ... 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust ... the exam easy and painless. MDLinx offers thousands of board-exam style questions and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... to patients and family members, medical professionals, and researchers, covering a variety of ... conference is a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
... researchers, physicians, technologists and medical experts from across ... to explore topics in nuclear medicine, molecular imaging, ... Mid-Winter Meetings. , Four meetings were held ... Educational Symposium of the American College of Nuclear ...
... NEW YORK , Feb. 9 As part ... development of life-transforming treatments and a cure for Parkinson,s disease, ... in total funding for seven research projects aiming to push ... therapeutic development. , While new genetic and cellular targets ...
... Feb. 9 Chiquita Brands International, Inc. (NYSE: ... Fresh Produce Association Foundation,s " A Salad Bar in Every ... health commitment by Chiquita and its Fresh Express subsidiary will ... across America.  Chiquita is the first produce company to commit ...
... clinical data for nearly 800 patients with non-small cell lung ... with age and sex specific patterns of increased or decreased ... issue of JAMA . The five-year overall survival ... remains the leading cause of cancer-related death in the United ...
... People with cystic fibrosis, an inherited disease that clogs ... defy treatment. While the life expectancy for children with ... many lives are still shortened in young adulthood by ... are often caused by common, environmental microbes that mutate ...
... First Lady Michelle ... number of chronic diseases including diabetes, heart disease, osteoarthritis, and sleep apnea. ... Washington, DC (Vocus) February 9, ... a risk factor for a number of chronic diseases including diabetes, heart disease, osteoarthritis, and ...
Cached Medicine News:Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 2Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 2Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 4Health News:Chiquita Announces Support for School Salad Bar Campaign 2Health News:Chiquita Announces Support for School Salad Bar Campaign 3Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 2Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 3Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 2Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 3Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 2Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 3
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Inquire...
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
Inquire...
Medicine Products: